Home Stock Ideas Long Ideas Healthcare  Summary AbbVie is a compelling 'Buy' as it has strong momentum in existing drugs and has a robust pipeline. Robust Q1 2026 results: net revenue up 12.4% YoY, driven by Immunology (Skyrizi +29%, Rinvoq +20%) and Neuroscience (+24%). Management raised 2026 EPS guidance to $14.18, signaling 42% YoY growth and confidence in ABBV’s diversified growth drivers and pipeline. With a 3.4% yield, strong balance sheet, and double-digit EPS growth outlook, ABBV is rated ‘Buy’ for income and growth-focused investors. Looking for a portfolio of ideas like this one? Members of iREIT®+HOYA Capital get exclusive access to our subscriber-only portfolios. Learn More » PM Images/DigitalVision via Getty Images Not every stock has to be a slam dunk investment. Rather, it helps to put an owner’s hat on whenever one buys a stock with a durable track record.…